Novartis Stock Falls 12% on Its Third Trial Setback In a Week
Novartis AG (NVS) fell 12.40% premarket after its Phase III HARBOR study for del-desiran failed, showing no significant improvement over placebo. This is the third setback in a week, following failures of pelacarsen and pauses in rap-cel trials. Barclays expects shares to underperform and questioned the company's sector premium. Novartis reiterated its 5-6% sales growth target through 2030, but Jefferies suggested it may require further M&A.
How this was made
The 30-second read
Why it matters
A Phase III failure plus additional pipeline setbacks (pelacarsen miss, rap-cel pauses after deaths) likely compresses valuation multiples and increases uncertainty around near-to-mid-term catalysts.
Market read
Traders can act on a fresh clinical-trial failure that directly challenges pipeline value and the market’s confidence in the Avidity-linked strategy.
What to watch
The article does not specify whether del-desiran’s failure was due to design/endpoint issues versus true lack of efficacy, which could affect how investors discount future readouts.
Background
Novartis’ del-desiran is part of its neuromuscular pipeline tied to the Avidity Biosciences acquisition, and the article frames this as the third setback in a week.
Ticker impact
Novartis shares fell premarket after del-desiran failed Phase III HARBOR in myotonic dystrophy type 1, with no significant placebo improvement.
Bearish near-term, with elevated volatility until management provides next-step clarity on del-desiran and the broader neuromuscular pipeline.
The article cites a Phase III setback plus multiple other trial pauses/deaths in the same pipeline, directly pressuring expected peak sales and deal-premium assumptions.
Market effects
Reinforces heightened clinical-risk pricing for antibody-oligonucleotide conjugate and neuromuscular pipeline programs, potentially pressuring peer sentiment.
Limited direct regional spillover beyond European large-cap pharma risk appetite, but could weigh on Swiss pharma sentiment.
Global biotech investors may reprice similar late-stage trial risk, especially for neuromuscular and ADC-adjacent modalities.
Counterpoint
The company reiterated its 2030 sales growth target, suggesting management may believe the overall portfolio can absorb del-desiran’s failure without breaking the long-term thesis.
Key entities
- companyNovartis AG
Swiss drugmaker whose del-desiran Phase III HARBOR study failed, driving a sharp premarket drop.
- companyAvidity Biosciences
Acquired by Novartis for about $12B; del-desiran is linked to this deal and its risk-adjusted sales assumptions.
- drug_programdel-desiran
Antibody oligonucleotide conjugate therapy that failed Phase III HARBOR in myotonic dystrophy type 1.
- drug_programpelacarsen
Earlier trial miss cited as part of the week’s setbacks.
- drug_programrap-cel
Cell therapy whose trials were paused after three patient deaths, per the article.
